Literature DB >> 33106894

Inflammatory milieu of muscle biopsies in juvenile dermatomyositis.

Erdal Sag1, Gulsev Kale2, Goknur Haliloglu3, Yelda Bilginer4, Zuhal Akcoren2, Diclehan Orhan2, Safak Gucer2, Haluk Topaloglu3, Seza Ozen4, Beril Talim2.   

Abstract

Juvenile dermatomyositis (JDM) is an inflammatory myopathy which causes severe morbidity and high mortality if untreated. In this study, we aimed to define the T-helper cell profile in the muscle biopsies of JDM patients. Muscle biopsies of twenty-six patients (50% female) were included in the study. Immunohistochemical expression of CD3, CD20, CD138, CD68, IL-17, Foxp3, IFN-ɣ, IFN-alpha and IL-4 was studied and muscle biopsies were scored using the JDM muscle biopsy scoring tool. Inflammatory cells were in small clusters in perimysium and perivascular area or scattered throughout the endomysium in most biopsies; however in 2 biopsies, lymphoid follicle-like big clusters were observed, and in one, there was a very dense and diffuse inflammatory infiltration nearly destroying all the muscle architecture. Seventy-three per cent of the biopsies had T cells, 88% had B cells, 57% had plasma cells, and all had macrophages. As for T-helper cell subtypes, 80% of the biopsies were Th1 positive, 92% Th17 positive and 30% Treg positive. No IL-4 positive inflammatory cell was detected, and only 2 biopsies showed IFN-alpha positivity. The mean JDM biopsy score was 17.6, meaning moderate to severe muscular involvement. Visual analogue score of the pathologist was strongly correlated with histopathological features. B cells, macrophages, plasma cells and T cells constitute the inflammatory milieu of the JDM muscle biopsies. As for T cells, JDM is a disease mainly related with Th1 and Th17 T-helper cell subtypes and to some extend Treg. Th2 cells are not involved in the pathogenesis.

Entities:  

Keywords:  B cells; Inflammatory cells; JDM; Muscle biopsy; T cells

Year:  2020        PMID: 33106894     DOI: 10.1007/s00296-020-04735-w

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  40 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Polymyositis and dermatomyositis (second of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-20       Impact factor: 91.245

Review 3.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 4.  Pathogenesis of dermatomyositis: role of cytokines and interferon.

Authors:  Lily Kao; Lorinda Chung; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

5.  Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.

Authors:  I Lundberg; A K Ulfgren; P Nyberg; U Andersson; L Klareskog
Journal:  Arthritis Rheum       Date:  1997-05

Review 6.  Cytokines in idiopathic inflammatory myopathies.

Authors:  Stina Salomonsson; Ingrid E Lundberg
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

7.  Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis.

Authors:  G Chevrel; G Page; C Granet; N Streichenberger; A Varennes; P Miossec
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

Review 8.  Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.

Authors:  Lucy R Wedderburn; Lisa G Rider
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

9.  MHC Class I overexpression on muscles in early juvenile dermatomyositis.

Authors:  Charles K C Li; Hemlata Varsani; Janice L Holton; Bin Gao; Patricia Woo; Lucy R Wedderburn
Journal:  J Rheumatol       Date:  2004-03       Impact factor: 4.666

Review 10.  Type I interferon pathway in adult and juvenile dermatomyositis.

Authors:  Emily C Baechler; Hatice Bilgic; Ann M Reed
Journal:  Arthritis Res Ther       Date:  2011-12-22       Impact factor: 5.156

View more
  4 in total

1.  Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis.

Authors:  Corinna Preuße; Barbara Paesler; Christopher Nelke; Derya Cengiz; Thomas Müntefering; Andreas Roos; Damien Amelin; Yves Allenbach; Akinori Uruha; Carsten Dittmayer; Andreas Hentschel; Marc Pawlitzki; Sarah Hoffmann; Sara Timm; Sarah Leonard Louis; Nora F Dengler; Heinz Wiendl; Jan D Lünemann; Albert Sickmann; Baptiste Hervier; Sven G Meuth; Udo Schneider; Anne Schänzer; Sabine Krause; Stylianos Tomaras; Eugen Feist; Rebecca Hasseli; Hans-Hilmar Goebel; Laure Gallay; Nathalie Streichenberger; Olivier Benveniste; Werner Stenzel; Tobias Ruck
Journal:  Acta Neuropathol       Date:  2022-05-25       Impact factor: 15.887

Review 2.  Can Exercise-Induced Muscle Damage Be a Good Model for the Investigation of the Anti-Inflammatory Properties of Diet in Humans?

Authors:  Spyridon Methenitis; Ioanna Stergiou; Smaragdi Antonopoulou; Tzortzis Nomikos
Journal:  Biomedicines       Date:  2021-01-05

3.  Morphological Characteristics of Idiopathic Inflammatory Myopathies in Juvenile Patients.

Authors:  Anne Schänzer; Leonie Rager; Iris Dahlhaus; Carsten Dittmayer; Corinna Preusse; Adela Della Marina; Hans-Hilmar Goebel; Andreas Hahn; Werner Stenzel
Journal:  Cells       Date:  2021-12-30       Impact factor: 6.600

4.  Hsp90 as a Myokine: Its Association with Systemic Inflammation after Exercise Interventions in Patients with Myositis and Healthy Subjects.

Authors:  Xiao Švec; Hana Štorkánová; Maja Špiritović; Kryštof Slabý; Sabína Oreská; Aneta Pekáčová; Barbora Heřmánková; Kristýna Bubová; Petr Česák; Haya Khouri; Gulalai Amjad; Heřman Mann; Martin Komarc; Karel Pavelka; Ladislav Šenolt; Josef Zámečník; Jiří Vencovský; Michal Tomčík
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.